IGF-1 DES (Des(1-3) IGF-1)

Truncated IGF-1 Analog · Localized Muscle Growth

Research use onlyGBP reference pricing where listedUK dispatch on catalogue items

Overview

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is…

IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire…

Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.

Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.

Accelerates local tissue recovery in the injected muscle group after training.

Mechanism

Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.

Research areas

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is…
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire…
Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
Accelerates local tissue recovery in the injected muscle group after training.

Research notes

Hypoglycemia -- consume carbohydrates after injection
Localized swelling and soreness at injection site
Increased pump in targeted muscles
Mild lightheadedness shortly after injection
Severe or recurring hypoglycemia despite carbohydrate intake

Literature

IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.

References

Questions

Why is IGF-1 DES injected directly into muscles?

IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.

Will IGF-1 DES cause hypoglycemia?

Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.

Can I use IGF-1 DES if I'm on a keto diet?

Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.